Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Tuberculosis | Technical advance

A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns

Authors: Valerie Flore Donkeng-Donfack, Jules Brice Tchatchueng-Mbougua, Ngu Njei Abanda, Suzanne Magloire Ongboulal, Yvonne Josiane Djieugoue, Yannick Kamdem Simo, Micheline Mekemnang Tchoupa, Frédéric Bekang Angui, Albert Kuate Kuate, Vincent Mbassa, Edwige Mvondo Abeng Belinga, Sara Eyangoh

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Active tuberculosis (TB) case finding is important as it helps detect pulmonary TB cases missed by the other active screening methods. It requires periodic mass screening in risk population groups such as prisoners and refugees. Unfortunately, in these risk population groups periodic mass screening can be challenging due to lengthy turnaround time (TAT), cost and implementation constraints. The aim of this study was to evaluate a diagnostic algorithm that can reduce the TAT and cost for TB and Rifampicin resistance (RR) detection. The algorithm involves testing with TB-LAMP followed by Xpert MTB/RIF for positive TB-LAMP cases to diagnose TB during mass campaigns in prisons and refugee camps.

Methods

The National Tuberculosis Control Program (NTCP) organized routine TB mass-screening campaigns in 34 prisons and 3 villages with refugees camps in Cameroon in 2019. TB LAMP was used for initial TB diagnosis and all TB-LAMP positive cases tested with the Xpert MTB/RIF assay to determine RR. TAT and cost benefits analysis of the combined use of TB-LAMP and Xpert MTB/RIF assays was determined and compared to the Xpert MTB/RIF assay when used only.

Results

A total of 4075 sputum samples were collected from TB presumptive, 3672 cases in 34 prisons and 403 samples in 3 villages. Of the 4,075 samples screened with TB-LAMP, 135 were TB positive (3.31%) and run on the Xpert MTB/RIF. Of the 135 positives cases, Xpert MTB/RIF revealed 3 were RR (2.22%). The use of TB-LAMP followed by testing with Xpert MTB/RIF for TB and RR detection reduced the TAT by 73.23% in prisons and 74.92% in villages. In addition to a reduced TAT, the two molecular tests used in synergy is cost benefit from year 2 onwards.

Conclusion

This study demonstrates the advantages of a diagnostic algorithm based on an initial testing with TB-LAMP followed by testing with Xpert MTB/RIF for TB diagnosis. This approach improved early and rapid TB detection with an added advantage of providing RR status. The proposed algorithm is effective and less costly from the second year of implementation and should be used by TB control programs.
Appendix
Available only for authorised users
Literature
2.
go back to reference Lönnroth K, Corbett E, Golub J, Godfrey-Faussett P, Uplekar M, Weil D, et al. Systematic screening for active tuberculosis: rationale, definitions and key considerations. Int J Tuberc Lung Dis. 2013;17(3):289–98.CrossRef Lönnroth K, Corbett E, Golub J, Godfrey-Faussett P, Uplekar M, Weil D, et al. Systematic screening for active tuberculosis: rationale, definitions and key considerations. Int J Tuberc Lung Dis. 2013;17(3):289–98.CrossRef
4.
go back to reference Gurbanova E, Mehdiyev R, Blondal K, Altraja A. Rapid tests reduce the burden of tuberculosis in Azerbaijan prisons: special emphasis on rifampicin-resistance. Rev Espanola Sanid Penit. 2018;20(3):111–20. Gurbanova E, Mehdiyev R, Blondal K, Altraja A. Rapid tests reduce the burden of tuberculosis in Azerbaijan prisons: special emphasis on rifampicin-resistance. Rev Espanola Sanid Penit. 2018;20(3):111–20.
5.
go back to reference Noeske J, Ndi N, Mbondi S. Controlling tuberculosis in prisons against confinement conditions: a lost case? Experience from Cameroon. Int J Tuberc Lung Dis. 2011;15(2):223–7.PubMed Noeske J, Ndi N, Mbondi S. Controlling tuberculosis in prisons against confinement conditions: a lost case? Experience from Cameroon. Int J Tuberc Lung Dis. 2011;15(2):223–7.PubMed
6.
go back to reference O’Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, et al. Tuberculosis in prisons in sub-Saharan Africa—the need for improved health services, surveillance and control. Tuberc Edinb Scotl. 2011;91(2):173–8. O’Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, et al. Tuberculosis in prisons in sub-Saharan Africa—the need for improved health services, surveillance and control. Tuberc Edinb Scotl. 2011;91(2):173–8.
7.
go back to reference Busatto C, de Nunes LS, de Valim ARM, Valença MS, Krug SF, Becker D, et al. Tuberculosis among prison staff in Rio Grande do Sul. Rev Bras Enferm. 2017;70(2):370–5.CrossRef Busatto C, de Nunes LS, de Valim ARM, Valença MS, Krug SF, Becker D, et al. Tuberculosis among prison staff in Rio Grande do Sul. Rev Bras Enferm. 2017;70(2):370–5.CrossRef
8.
go back to reference Reis AJ, de David SMM, de Nunes LS, de Valim ARM, Possuelo LG. Recent transmission of drug-resistant Mycobacterium tuberculosis in a prison population in southern Brazil. J Bras Pneumol. 2016;42(4):286–9.CrossRef Reis AJ, de David SMM, de Nunes LS, de Valim ARM, Possuelo LG. Recent transmission of drug-resistant Mycobacterium tuberculosis in a prison population in southern Brazil. J Bras Pneumol. 2016;42(4):286–9.CrossRef
9.
go back to reference Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health. 2006;120(1):33–41.CrossRef Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health. 2006;120(1):33–41.CrossRef
10.
go back to reference National Tuberculosis Control Program. 2020 Cameroun National TB Evaluation report. 2021. National Tuberculosis Control Program. 2020 Cameroun National TB Evaluation report. 2021.
11.
go back to reference Noeske J, Ndi N, Elo GA, Mfondih SM. Tuberculosis incidence in Cameroonian prisons: a 1-year prospective study. South Afr Med J S. 2014;104(3):209–11.CrossRef Noeske J, Ndi N, Elo GA, Mfondih SM. Tuberculosis incidence in Cameroonian prisons: a 1-year prospective study. South Afr Med J S. 2014;104(3):209–11.CrossRef
20.
go back to reference Donfack VF, Ngando L, Pefura EW, Che DS, Ateba G, Bigna JJ, et al. Comparative study of LoopampTM Mycobacterium tuberculosis complex kit for rapid detection of Mycobacterium tuberculosis complex in cameroon. Biomed Biotechnol Res J. 2018;2:46–52.CrossRef Donfack VF, Ngando L, Pefura EW, Che DS, Ateba G, Bigna JJ, et al. Comparative study of LoopampTM Mycobacterium tuberculosis complex kit for rapid detection of Mycobacterium tuberculosis complex in cameroon. Biomed Biotechnol Res J. 2018;2:46–52.CrossRef
21.
go back to reference Priya BS, Katherine F, Luke S, Christen MG, Adithya C. Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2019;19:268.CrossRef Priya BS, Katherine F, Luke S, Christen MG, Adithya C. Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2019;19:268.CrossRef
24.
go back to reference Levin HM, McEwan PJ. Cost-effectiveness analysis: methods and applications. 2nd ed. Thousand Oaks: Sage Publications; 2001. Levin HM, McEwan PJ. Cost-effectiveness analysis: methods and applications. 2nd ed. Thousand Oaks: Sage Publications; 2001.
25.
go back to reference Ndlovu Z, Fajardo E, Mbofana E, Maparo T, Garone D, Metcalf C, et al. Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe. PLoS ONE. 2018;13(3):e0193577.CrossRef Ndlovu Z, Fajardo E, Mbofana E, Maparo T, Garone D, Metcalf C, et al. Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe. PLoS ONE. 2018;13(3):e0193577.CrossRef
27.
go back to reference TB-LAMP test now available for $6 through Global Drug Facility. 2020 Available in the GDF diagnostics catalog. HumaLoop T TB-LAMP test now available for $6 through Global Drug Facility. 2020 Available in the GDF diagnostics catalog. HumaLoop T
Metadata
Title
A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
Authors
Valerie Flore Donkeng-Donfack
Jules Brice Tchatchueng-Mbougua
Ngu Njei Abanda
Suzanne Magloire Ongboulal
Yvonne Josiane Djieugoue
Yannick Kamdem Simo
Micheline Mekemnang Tchoupa
Frédéric Bekang Angui
Albert Kuate Kuate
Vincent Mbassa
Edwige Mvondo Abeng Belinga
Sara Eyangoh
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07157-0

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue